Term
|
Definition
| Insulin Monomer with Rapid Onset, Peak and Duration |
|
|
Term
|
Definition
| Insulin Monomer with Rapid Onset, Peak and Duration |
|
|
Term
|
Definition
| Insulin Monomer with Rapid Onset, Peak and Duration |
|
|
Term
|
Definition
| Hexamer Crystalline Zinc-Insulin Complex. The Dissociation from Hexamer to Monomer is the rate limiting Step. Rapid Acting |
|
|
Term
|
Definition
| Insulin altered to be completely soluble at pH of 4.0. When injected into tissue (pH = 7.4) is precipitates and then slowly dissolves giving Long Action and No Peak. |
|
|
Term
|
Definition
| Insulin with a Fatty Acid addition which promotes protein binding slowing absorption, action, and clearance. Long Acting and No Peak. |
|
|
Term
|
Definition
| 2nd Generation Sulfonylurea |
|
|
Term
|
Definition
| 2nd Generation Sulfonylurea |
|
|
Term
|
Definition
| 3rd Generation Sulfonylurea |
|
|
Term
|
Definition
| Meglitinide with same action as Sulfoylurea |
|
|
Term
|
Definition
| Meglitinide with same action as Sulfoylurea |
|
|
Term
|
Definition
| AMP Kinase Activator which increases muscle uptake of glucose and decreases glucose production and synthesis of lipids by the liver. Anti-Hyperglycemic but does not cause Hypoglycemia. Watch Anion Gap (lactic acidosis) |
|
|
Term
|
Definition
| Activates PPAR-Gamma. Promotes fatty acid uptake and storage in adipose tissue rather than Skeletal Muscle or Liver. Causes skeletal muscle and liver to be less fatty and more sensitive to insulin. Requires insulin to act. Can cause plasma volume expansion worsening CHF. |
|
|
Term
|
Definition
Incretin Mimetic. GLP-1 agonist from Gila Monster Saliva
Twice Daily Injections |
|
|
Term
|
Definition
DPP-4 inhibitor: blocks degradation of GLP and GLP1
Oral once daily dose. |
|
|
Term
|
Definition
DPP-4 inhibitor: blocks degradation of GLP and GLP1
Oral once daily dose. |
|
|
Term
|
Definition
Amylin Analogue: decreases glucagon release and slows Gastric emptying. Useful in both Type 1 and 2 dibetes.
Injection |
|
|
Term
|
Definition
| Insulin with Intermediate Action. Comes in a suspension with protamine. Enzymes slowly degrade protamine which liberates the insulin. |
|
|
